New Drug Application Resubmitted for Istradefylline for Parkinson's Disease OFF Periods

A new drug application has been resubmitted to the Food and Drug Administration (FDA) for istradefylline (KW-6002; Kyowa Hakko Kirin Co., Ltd., Tokyo, Japan). Istradefylline has been investigated as an adjunctive treatment to levodopa/carbidopa for Parkinson’s disease OFF symptoms.

Istradefylline is an investigational, selective adenosine A2A receptor antagonist approved in Japan for the adjunctive treatment of the wearing-off phenomenon but has no approved indication in the US. “Istradefylline is an A2A receptor antagonist, and if approved by FDA, may provide a novel, nondopaminergic, pharmacologic approach to treating ‘off’ episodes for people living with PD,” said Stuart Isaacson, MD, director, Parkinson’s Disease and Movement Disorders Center of Boca Raton.

Technology Has Potential to Halt Production of Mutated Protein in Huntington's Disease and Spinocerebellar Ataxia

Previous News Article

First Patients Dosed in Trial of Two-Drug Combination Therapy for Alzheimer's Disease

Next News Article
This Month's Issue
Brain Imaging in Differential Diagnosis of Dementia

Mathew R. Ayers, DO; Diana Svaldi, PhD; and Liana G. Apostolova, MD, MS